Ivosidenib is an innovative drug for specific types of acute myeloid leukemia (AML). Its efficacy and price have always been the focus of attention for patients and healthcare professionals. This article aims to delve into the cost of one course of Ivosidenib treatment, while also providing key information on the management of drug overdose and its pharmacokinetics, helping patients gain a more comprehensive understanding of this therapeutic drug.

How Much Does One Course of Ivosidenib Cost?

For many patients seeking Ivosidenib treatment, the cost of a treatment course is a primary consideration. With its unique inhibitory effect on the IDH1 target, Ivosidenib provides a new treatment option for AML patients carrying susceptible IDH1 mutations.

Overview of Market Prices

Currently on the market, Ivosidenib is mainly produced by Laos Lucius, with a specification of 250mg*60 tablets. The price of Laos Lucius' Ivosidenib is approximately 604 US dollars per box. Considering that the recommended dosage of Ivosidenib is 500mg per day (i.e., 2 tablets per day), one treatment course (usually one month, calculated as 30 days) requires 60 tablets. Therefore, one box of the drug is equivalent to the dosage needed for one treatment course.

Factors Affecting Costs

Although the above price is a reference market price, patients need to consider many factors when making actual purchases. Since Ivosidenib has not yet been included in medical insurance, patients must bear all costs themselves, which undoubtedly increases their economic burden. Therefore, choosing formal purchasing channels, paying attention to medical assistance programs, and rationally utilizing medical resources are crucial for reducing patients' economic pressure.

The cost of one course of Ivosidenib varies depending on the brand, specification, and purchasing channel, and patients need to make reasonable choices based on their own circumstances. At the same time, with the continuous improvement of medical policies and the intensification of market competition, the price of Ivosidenib is expected to become more affordable in the future.

Measures for Managing Ivosidenib Overdose

During the use of Ivosidenib, drug overdose is an issue that cannot be ignored. Excessive administration may lead to aggravated adverse reactions and even be life-threatening. Therefore, understanding and mastering the measures for managing drug overdose is crucial.

Acute Management Measures

In the event of a drug overdose, administration of Ivosidenib should be stopped immediately, and the patient's vital signs should be closely monitored. If severe adverse reactions occur, such as difficulty breathing, palpitations, or hypotension, the patient should be taken to the hospital immediately for necessary emergency treatment. At the same time, ensure the patient's airway is unobstructed to guarantee normal breathing.

Long-Term Monitoring and Adjustment

Even if no severe symptoms occur in the short term after an overdose, long-term monitoring is still necessary. In particular, regular electrocardiogram (ECG) tests and blood biochemical index checks should be conducted to promptly detect and address potential toxic reactions. In addition, based on the patient's specific condition, doctors may recommend adjusting the drug dosage or suspending treatment to ensure the patient's safety.

Therefore, in the case of Ivosidenib overdose, timely and correct management measures are key to ensuring the patient's life safety. At the same time, strengthening patient education and improving medication compliance are also important means to prevent drug overdose.

Pharmacokinetics of Ivosidenib

Pharmacokinetics is the science that studies the laws of drug absorption, distribution, metabolism, and excretion in the human body. For Ivosidenib, understanding its pharmacokinetic characteristics is helpful for optimizing treatment plans and improving therapeutic effects.

Absorption and Distribution

After oral administration, Ivosidenib is rapidly absorbed by the gastrointestinal tract, reaching a relatively high plasma concentration. After a single dose, the average peak plasma concentration (Cmax) is 4,503ng/mL, and the steady-state concentration is 6,551ng/mL. The drug is widely distributed in the body, capable of penetrating cell membranes and entering various tissues and organs to exert its therapeutic effect.

Metabolism and Excretion

Ivosidenib is mainly metabolized in the liver, forming a variety of metabolites. Some of these metabolites are active, while others are inactive. The drug and its metabolites are mainly excreted through the kidneys, and a portion is also excreted into the intestines through bile. The area under the steady-state concentration-time curve (AUC) is 117,348ng·hr/mL, which reflects the extent of drug exposure in the body.

Understanding the pharmacokinetic characteristics of Ivosidenib is of great significance for guiding clinical medication and optimizing treatment plans. It also reminds patients to closely monitor changes in liver and kidney function during medication to ensure the safe use of the drug.